Literature DB >> 15855506

Growth cycle-dependent pharmacodynamics of antichlamydial drugs.

Katrin Siewert1, Jan Rupp, Matthias Klinger, Werner Solbach, Jens Gieffers.   

Abstract

Chlamydiae are obligate intracellular pathogens that exhibit an extensive intracellular developmental cycle in vivo. Clinical treatment of chlamydial infection is typically initiated upon occurrence of symptomatology and is directed against an asynchronous population of different chlamydial developmental forms. Pharmacodynamics of antichlamydial drugs are predominantly characterized by MICs; however, in vitro determinations of MIC may not reflect differential susceptibilities of the developmental cycle. In this study, we correlated the antichlamydial effect of erythromycin, rifampin, doxycycline, and ciprofloxacin with the developmental stage of a fast-replicating and a slow-replicating chlamydial species. In addition, we describe the influence of concentration on killing. Extracellular elementary bodies and very-early-phase and late-phase chlamydiae were refractory to all tested antibiotics except rifampin, which was very effective against early-cycle chlamydiae. Rifampin was the most effective antibiotic overall, killed in a dose dependent matter, and exhibited moderate synergism with erythromycin. These considerations provide important information on chlamydial biology and antimicrobial susceptibility. A combinational therapy of rifampin and a macrolide should be considered in therapy-refractory infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855506      PMCID: PMC1087662          DOI: 10.1128/AAC.49.5.1852-1856.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.

Authors:  J Gieffers; H Füllgraf; J Jahn; M Klinger; K Dalhoff; H A Katus; W Solbach; M Maass
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

Review 2.  Chlamydia trachomatis: impact on human reproduction.

Authors:  J Paavonen; W Eggert-Kruse
Journal:  Hum Reprod Update       Date:  1999 Sep-Oct       Impact factor: 15.610

3.  Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.

Authors:  Andrei Kutlin; Patricia M Roblin; Margaret R Hammerschlag
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

4.  Rifampin in chlamydial infections.

Authors:  J Schachter
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

5.  Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis.

Authors:  K Wolf; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; B Jürgens-Saathoff; A P Hudson; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp.

Authors:  R J Suchland; W M Geisler; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.

Authors:  T S Moulding; H Q Le; D Rikleen; P Davidson
Journal:  Int J Tuberc Lung Dis       Date:  2004-06       Impact factor: 2.373

9.  Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis.

Authors:  Ute Dreses-Werringloer; Ingrid Padubrin; Lars Köhler; Alan P Hudson
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis.

Authors:  Robert J Belland; Guangming Zhong; Deborah D Crane; Daniel Hogan; Daniel Sturdevant; Jyotika Sharma; Wandy L Beatty; Harlan D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

View more
  6 in total

Review 1.  Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember?

Authors:  Kensuke Shima; Gregor Kuhlenbäumer; Jan Rupp
Journal:  Med Microbiol Immunol       Date:  2010-05-06       Impact factor: 3.402

2.  Chlamydia pneumoniae infection in polarized epithelial cell lines.

Authors:  Liisa Törmäkangas; Eveliina Markkula; Kari Lounatmaa; Mirja Puolakkainen
Journal:  Infect Immun       Date:  2010-03-29       Impact factor: 3.441

3.  Novel Detection Strategy To Rapidly Evaluate the Efficacy of Antichlamydial Agents.

Authors:  Yan Zhang; Yuqi Xian; Leiqiong Gao; Hiba Elaasar; Yao Wang; Lamiya Tauhid; Ziyu Hua; Li Shen
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.

Authors:  Kensuke Shima; Márta Szaszák; Werner Solbach; Jens Gieffers; Jan Rupp
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

Review 5.  Scrub Typhus and the Misconception of Doxycycline Resistance.

Authors:  Tri Wangrangsimakul; Weerawat Phuklia; Paul N Newton; Allen L Richards; Nicholas P J Day
Journal:  Clin Infect Dis       Date:  2020-05-23       Impact factor: 9.079

6.  Amphipathic β2,2-Amino Acid Derivatives Suppress Infectivity and Disrupt the Intracellular Replication Cycle of Chlamydia pneumoniae.

Authors:  Leena Hanski; Dominik Ausbacher; Terttu M Tiirola; Morten B Strøm; Pia M Vuorela
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.